
No change: table 0 0 H
  First character (Section) is value 0: Medical and Surgical
  Second character (Body System) is value 0: Central Nervous System and Cranial Nerves
  Third character (Operation) is value H: Insertion: Putting in a nonbiological appliance that monitors, assists, performs, or prevents a physiological function but does not physically take the place of a body part

FY2024: First panel of table 0 0 H
  Fourth character (Body Part) is value 0: Brain
  Fifth character (Approach) is value 0: Open
  Sixth character (Device) has 7 choices.
    First choice is value 1: Radioactive Element
    Second choice is value 2: Monitoring Device
    Third choice is value 3: Infusion Device
    Fourth choice is value 4: Radioactive Element, Cesium-131 Collagen Implant
    Fifth choice is value 5: Radioactive Element, Palladium-103 Collagen Implant
    Sixth choice is value M: Neurostimulator Lead
    Seventh choice is value Y: Other Device
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Second panel of table 0 0 H
  Fourth character (Body Part) is value 0: Brain
  Fifth character (Approach) has 2 choices.
    First choice is value 3: Percutaneous
    Second choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) has 5 choices.
    First choice is value 1: Radioactive Element
    Second choice is value 2: Monitoring Device
    Third choice is value 3: Infusion Device
    Fourth choice is value M: Neurostimulator Lead
    Fifth choice is value Y: Other Device
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Third panel of table 0 0 H
  Fourth character (Body Part) has 4 choices.
    First choice is value 6: Cerebral Ventricle
    Second choice is value E: Cranial Nerve
    Third choice is value U: Spinal Canal
    Fourth choice is value V: Spinal Cord
  Fifth character (Approach) has 3 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) has 5 choices.
    First choice is value 1: Radioactive Element
    Second choice is value 2: Monitoring Device
    Third choice is value 3: Infusion Device
    Fourth choice is value M: Neurostimulator Lead
    Fifth choice is value Y: Other Device
  Seventh character (Qualifier) is value Z: No Qualifier

No change: table 0 2 5
  First character (Section) is value 0: Medical and Surgical
  Second character (Body System) is value 2: Heart and Great Vessels
  Third character (Operation) is value 5: Destruction: Physical eradication of all or a portion of a body part by the direct use of energy, force, or a destructive agent

FY2024: First panel of table 0 2 5
  Fourth character (Body Part) has 21 choices.
    First choice is value 4: Coronary Vein
    Second choice is value 5: Atrial Septum
    Third choice is value 6: Atrium, Right
    Fourth choice is value 9: Chordae Tendineae
    Fifth choice is value D: Papillary Muscle
    Sixth choice is value F: Aortic Valve
    Seventh choice is value G: Mitral Valve
    Eighth choice is value H: Pulmonary Valve
    Ninth choice is value J: Tricuspid Valve
    Tenth choice is value K: Ventricle, Right
    Eleventh choice is value L: Ventricle, Left
    Twelfth choice is value M: Ventricular Septum
    Thirteenth choice is value N: Pericardium
    Fourteenth choice is value P: Pulmonary Trunk
    Fifteenth choice is value Q: Pulmonary Artery, Right
    Sixteenth choice is value R: Pulmonary Artery, Left
    Seventeenth choice is value S: Pulmonary Vein, Right
    Eighteenth choice is value T: Pulmonary Vein, Left
    Nineteenth choice is value V: Superior Vena Cava
    Twentieth choice is value W: Thoracic Aorta, Descending
    Twenty-first choice is value X: Thoracic Aorta, Ascending/Arch
  Fifth character (Approach) has 3 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Second panel of table 0 2 5
  Fourth character (Body Part) is value 7: Atrium, Left
  Fifth character (Approach) has 3 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 2 choices.
    First choice is value K: Left Atrial Appendage
    Second choice is value Z: No Qualifier

FY2024: Third panel of table 0 2 5
  Fourth character (Body Part) is value 8: Conduction Mechanism
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) is value Z: No Qualifier

FY2024: Fourth panel of table 0 2 5
  Fourth character (Body Part) is value 8: Conduction Mechanism
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 2 choices.
    First choice is value F: Irreversible Electroporation
    Second choice is value Z: No Qualifier

FY2024: table 0 7 T
  First character (Section) is value 0: Medical and Surgical
  Second character (Body System) is value 7: Lymphatic and Hemic Systems
  Third character (Operation) is value T: Resection: Cutting out or off, without replacement, all of a body part

FY2024: First panel of table 0 7 T
  Fourth character (Body Part) has 20 choices.
    First choice is value 0: Lymphatic, Head
    Second choice is value 1: Lymphatic, Right Neck
    Third choice is value 2: Lymphatic, Left Neck
    Fourth choice is value 3: Lymphatic, Right Upper Extremity
    Fifth choice is value 4: Lymphatic, Left Upper Extremity
    Sixth choice is value 5: Lymphatic, Right Axillary
    Seventh choice is value 6: Lymphatic, Left Axillary
    Eighth choice is value 7: Lymphatic, Thorax
    Ninth choice is value 8: Lymphatic, Internal Mammary, Right
    Tenth choice is value 9: Lymphatic, Internal Mammary, Left
    Eleventh choice is value B: Lymphatic, Mesenteric
    Twelfth choice is value C: Lymphatic, Pelvis
    Thirteenth choice is value D: Lymphatic, Aortic
    Fourteenth choice is value F: Lymphatic, Right Lower Extremity
    Fifteenth choice is value G: Lymphatic, Left Lower Extremity
    Sixteenth choice is value H: Lymphatic, Right Inguinal
    Seventeenth choice is value J: Lymphatic, Left Inguinal
    Eighteenth choice is value K: Thoracic Duct
    Nineteenth choice is value L: Cisterna Chyli
    Twentieth choice is value M: Thymus
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) is value Z: No Qualifier

FY2024: Second panel of table 0 7 T
  Fourth character (Body Part) is value P: Spleen
  Fifth character (Approach) is value 0: Open
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) is value Z: No Qualifier

FY2024: Third panel of table 0 7 T
  Fourth character (Body Part) is value P: Spleen
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 2 choices.
    First choice is value G: Hand-Assisted
    Second choice is value Z: No Qualifier

No change: table 0 9 7
  First character (Section) is value 0: Medical and Surgical
  Second character (Body System) is value 9: Ear, Nose, Sinus
  Third character (Operation) is value 7: Dilation: Expanding an orifice or the lumen of a tubular body part

No change: First panel of table 0 9 7
  Fourth character (Body Part) has 2 choices.
    First choice is value F: Eustachian Tube, Right
    Second choice is value G: Eustachian Tube, Left
  Fifth character (Approach) has 3 choices.
    First choice is value 0: Open
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Device) has 2 choices.
    First choice is value D: Intraluminal Device
    Second choice is value Z: No Device
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Second panel of table 0 9 7
  Fourth character (Body Part) has 2 choices.
    First choice is value F: Eustachian Tube, Right
    Second choice is value G: Eustachian Tube, Left
  Fifth character (Approach) has 2 choices.
    First choice is value 3: Percutaneous
    Second choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) is value Z: No Qualifier

FY2024: Third panel of table 0 9 7
  Fourth character (Body Part) is value N: Nasopharynx
  Fifth character (Approach) has 3 choices.
    First choice is value 0: Open
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) is value Z: No Qualifier

No change: table 0 D B
  First character (Section) is value 0: Medical and Surgical
  Second character (Body System) is value D: Gastrointestinal System
  Third character (Operation) is value B: Excision: Cutting out or off, without replacement, a portion of a body part

FY2024: First panel of table 0 D B
  Fourth character (Body Part) has 15 choices.
    First choice is value 1: Esophagus, Upper
    Second choice is value 2: Esophagus, Middle
    Third choice is value 3: Esophagus, Lower
    Fourth choice is value 4: Esophagogastric Junction
    Fifth choice is value 5: Esophagus
    Sixth choice is value 7: Stomach, Pylorus
    Seventh choice is value 8: Small Intestine
    Eighth choice is value 9: Duodenum
    Ninth choice is value A: Jejunum
    Tenth choice is value B: Ileum
    Eleventh choice is value C: Ileocecal Valve
    Twelfth choice is value E: Large Intestine
    Thirteenth choice is value H: Cecum
    Fourteenth choice is value K: Ascending Colon
    Fifteenth choice is value P: Rectum
  Fifth character (Approach) has 5 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
    Fourth choice is value 7: Via Natural or Artificial Opening
    Fifth choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 2 choices.
    First choice is value X: Diagnostic
    Second choice is value Z: No Qualifier

No change: Second panel of table 0 D B
  Fourth character (Body Part) is value 6: Stomach
  Fifth character (Approach) has 5 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
    Fourth choice is value 7: Via Natural or Artificial Opening
    Fifth choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 3 choices.
    First choice is value 3: Vertical
    Second choice is value X: Diagnostic
    Third choice is value Z: No Qualifier

FY2024: Third panel of table 0 D B
  Fourth character (Body Part) has 2 choices.
    First choice is value F: Large Intestine, Right
    Second choice is value J: Appendix
  Fifth character (Approach) has 4 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 7: Via Natural or Artificial Opening
    Fourth choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 2 choices.
    First choice is value X: Diagnostic
    Second choice is value Z: No Qualifier

FY2024: Fourth panel of table 0 D B
  Fourth character (Body Part) has 2 choices.
    First choice is value F: Large Intestine, Right
    Second choice is value J: Appendix
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 3 choices.
    First choice is value G: Hand-Assisted
    Second choice is value X: Diagnostic
    Third choice is value Z: No Qualifier

FY2024: Fifth panel of table 0 D B
  Fourth character (Body Part) has 4 choices.
    First choice is value G: Large Intestine, Left
    Second choice is value L: Transverse Colon
    Third choice is value M: Descending Colon
    Fourth choice is value N: Sigmoid Colon
  Fifth character (Approach) has 4 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 7: Via Natural or Artificial Opening
    Fourth choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 2 choices.
    First choice is value X: Diagnostic
    Second choice is value Z: No Qualifier

FY2024: Sixth panel of table 0 D B
  Fourth character (Body Part) has 4 choices.
    First choice is value G: Large Intestine, Left
    Second choice is value L: Transverse Colon
    Third choice is value M: Descending Colon
    Fourth choice is value N: Sigmoid Colon
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 3 choices.
    First choice is value G: Hand-Assisted
    Second choice is value X: Diagnostic
    Third choice is value Z: No Qualifier

No change: Seventh panel of table 0 D B
  Fourth character (Body Part) has 4 choices.
    First choice is value G: Large Intestine, Left
    Second choice is value L: Transverse Colon
    Third choice is value M: Descending Colon
    Fourth choice is value N: Sigmoid Colon
  Fifth character (Approach) is value F: Via Natural or Artificial Opening With Percutaneous Endoscopic Assistance
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Eighth panel of table 0 D B
  Fourth character (Body Part) is value Q: Anus
  Fifth character (Approach) has 6 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
    Fourth choice is value 7: Via Natural or Artificial Opening
    Fifth choice is value 8: Via Natural or Artificial Opening Endoscopic
    Sixth choice is value X: External
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 2 choices.
    First choice is value X: Diagnostic
    Second choice is value Z: No Qualifier

No change: Ninth panel of table 0 D B
  Fourth character (Body Part) has 4 choices.
    First choice is value R: Anal Sphincter
    Second choice is value U: Omentum
    Third choice is value V: Mesentery
    Fourth choice is value W: Peritoneum
  Fifth character (Approach) has 3 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 2 choices.
    First choice is value X: Diagnostic
    Second choice is value Z: No Qualifier

No change: table 0 D T
  First character (Section) is value 0: Medical and Surgical
  Second character (Body System) is value D: Gastrointestinal System
  Third character (Operation) is value T: Resection: Cutting out or off, without replacement, all of a body part

FY2024: First panel of table 0 D T
  Fourth character (Body Part) has 17 choices.
    First choice is value 1: Esophagus, Upper
    Second choice is value 2: Esophagus, Middle
    Third choice is value 3: Esophagus, Lower
    Fourth choice is value 4: Esophagogastric Junction
    Fifth choice is value 5: Esophagus
    Sixth choice is value 6: Stomach
    Seventh choice is value 7: Stomach, Pylorus
    Eighth choice is value 8: Small Intestine
    Ninth choice is value 9: Duodenum
    Tenth choice is value A: Jejunum
    Eleventh choice is value B: Ileum
    Twelfth choice is value C: Ileocecal Valve
    Thirteenth choice is value E: Large Intestine
    Fourteenth choice is value H: Cecum
    Fifteenth choice is value K: Ascending Colon
    Sixteenth choice is value P: Rectum
    Seventeenth choice is value Q: Anus
  Fifth character (Approach) has 4 choices.
    First choice is value 0: Open
    Second choice is value 4: Percutaneous Endoscopic
    Third choice is value 7: Via Natural or Artificial Opening
    Fourth choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) is value Z: No Qualifier

FY2024: Second panel of table 0 D T
  Fourth character (Body Part) has 2 choices.
    First choice is value F: Large Intestine, Right
    Second choice is value J: Appendix
  Fifth character (Approach) has 3 choices.
    First choice is value 0: Open
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) is value Z: No Qualifier

FY2024: Third panel of table 0 D T
  Fourth character (Body Part) has 2 choices.
    First choice is value F: Large Intestine, Right
    Second choice is value J: Appendix
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 2 choices.
    First choice is value G: Hand-Assisted
    Second choice is value Z: No Qualifier

FY2024: Fourth panel of table 0 D T
  Fourth character (Body Part) has 4 choices.
    First choice is value G: Large Intestine, Left
    Second choice is value L: Transverse Colon
    Third choice is value M: Descending Colon
    Fourth choice is value N: Sigmoid Colon
  Fifth character (Approach) has 4 choices.
    First choice is value 0: Open
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
    Fourth choice is value F: Via Natural or Artificial Opening With Percutaneous Endoscopic Assistance
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) is value Z: No Qualifier

FY2024: Fifth panel of table 0 D T
  Fourth character (Body Part) has 4 choices.
    First choice is value G: Large Intestine, Left
    Second choice is value L: Transverse Colon
    Third choice is value M: Descending Colon
    Fourth choice is value N: Sigmoid Colon
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 2 choices.
    First choice is value G: Hand-Assisted
    Second choice is value Z: No Qualifier

No change: Sixth panel of table 0 D T
  Fourth character (Body Part) has 2 choices.
    First choice is value R: Anal Sphincter
    Second choice is value U: Omentum
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) is value Z: No Qualifier

No change: table 0 D X
  First character (Section) is value 0: Medical and Surgical
  Second character (Body System) is value D: Gastrointestinal System
  Third character (Operation) is value X: Transfer: Moving, without taking out, all or a portion of a body part to another location to take over the function of all or a portion of a body part

No change: First panel of table 0 D X
  Fourth character (Body Part) is value 6: Stomach
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) is value 5: Esophagus

No change: Second panel of table 0 D X
  Fourth character (Body Part) is value 8: Small Intestine
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 5 choices.
    First choice is value 5: Esophagus
    Second choice is value B: Bladder
    Third choice is value C: Ureter, Right
    Fourth choice is value D: Ureter, Left
    Fifth choice is value F: Ureters, Bilateral

No change: Third panel of table 0 D X
  Fourth character (Body Part) is value E: Large Intestine
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 3 choices.
    First choice is value 5: Esophagus
    Second choice is value 7: Vagina
    Third choice is value B: Bladder

FY2024: Fourth panel of table 0 D X
  Fourth character (Body Part) is value U: Omentum
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 4 choices.
    First choice is value V: Thoracic Region
    Second choice is value W: Abdominal Region
    Third choice is value X: Pelvic Region
    Fourth choice is value Y: Inguinal Region

No change: table 0 F B
  First character (Section) is value 0: Medical and Surgical
  Second character (Body System) is value F: Hepatobiliary System and Pancreas
  Third character (Operation) is value B: Excision: Cutting out or off, without replacement, a portion of a body part

FY2024: First panel of table 0 F B
  Fourth character (Body Part) has 3 choices.
    First choice is value 0: Liver
    Second choice is value 1: Liver, Right Lobe
    Third choice is value 2: Liver, Left Lobe
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 2 choices.
    First choice is value X: Diagnostic
    Second choice is value Z: No Qualifier

FY2024: Second panel of table 0 F B
  Fourth character (Body Part) has 3 choices.
    First choice is value 0: Liver
    Second choice is value 1: Liver, Right Lobe
    Third choice is value 2: Liver, Left Lobe
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 3 choices.
    First choice is value G: Hand-Assisted
    Second choice is value X: Diagnostic
    Third choice is value Z: No Qualifier

FY2024: Third panel of table 0 F B
  Fourth character (Body Part) is value 4: Gallbladder
  Fifth character (Approach) has 4 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
    Fourth choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 2 choices.
    First choice is value X: Diagnostic
    Second choice is value Z: No Qualifier

No change: Fourth panel of table 0 F B
  Fourth character (Body Part) has 8 choices.
    First choice is value 5: Hepatic Duct, Right
    Second choice is value 6: Hepatic Duct, Left
    Third choice is value 7: Hepatic Duct, Common
    Fourth choice is value 8: Cystic Duct
    Fifth choice is value 9: Common Bile Duct
    Sixth choice is value C: Ampulla of Vater
    Seventh choice is value D: Pancreatic Duct
    Eighth choice is value F: Pancreatic Duct, Accessory
  Fifth character (Approach) has 5 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
    Fourth choice is value 7: Via Natural or Artificial Opening
    Fifth choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 2 choices.
    First choice is value X: Diagnostic
    Second choice is value Z: No Qualifier

FY2024: Fifth panel of table 0 F B
  Fourth character (Body Part) is value G: Pancreas
  Fifth character (Approach) has 3 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 2 choices.
    First choice is value X: Diagnostic
    Second choice is value Z: No Qualifier

FY2024: Sixth panel of table 0 F B
  Fourth character (Body Part) is value G: Pancreas
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 3 choices.
    First choice is value G: Hand-Assisted
    Second choice is value X: Diagnostic
    Third choice is value Z: No Qualifier

No change: table 0 F T
  First character (Section) is value 0: Medical and Surgical
  Second character (Body System) is value F: Hepatobiliary System and Pancreas
  Third character (Operation) is value T: Resection: Cutting out or off, without replacement, all of a body part

FY2024: First panel of table 0 F T
  Fourth character (Body Part) has 5 choices.
    First choice is value 0: Liver
    Second choice is value 1: Liver, Right Lobe
    Third choice is value 2: Liver, Left Lobe
    Fourth choice is value 4: Gallbladder
    Fifth choice is value G: Pancreas
  Fifth character (Approach) is value 0: Open
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) is value Z: No Qualifier

FY2024: Second panel of table 0 F T
  Fourth character (Body Part) has 5 choices.
    First choice is value 0: Liver
    Second choice is value 1: Liver, Right Lobe
    Third choice is value 2: Liver, Left Lobe
    Fourth choice is value 4: Gallbladder
    Fifth choice is value G: Pancreas
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 2 choices.
    First choice is value G: Hand-Assisted
    Second choice is value Z: No Qualifier

No change: Third panel of table 0 F T
  Fourth character (Body Part) has 8 choices.
    First choice is value 5: Hepatic Duct, Right
    Second choice is value 6: Hepatic Duct, Left
    Third choice is value 7: Hepatic Duct, Common
    Fourth choice is value 8: Cystic Duct
    Fifth choice is value 9: Common Bile Duct
    Sixth choice is value C: Ampulla of Vater
    Seventh choice is value D: Pancreatic Duct
    Eighth choice is value F: Pancreatic Duct, Accessory
  Fifth character (Approach) has 4 choices.
    First choice is value 0: Open
    Second choice is value 4: Percutaneous Endoscopic
    Third choice is value 7: Via Natural or Artificial Opening
    Fourth choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) is value Z: No Qualifier

No change: table 0 T T
  First character (Section) is value 0: Medical and Surgical
  Second character (Body System) is value T: Urinary System
  Third character (Operation) is value T: Resection: Cutting out or off, without replacement, all of a body part

FY2024: First panel of table 0 T T
  Fourth character (Body Part) has 3 choices.
    First choice is value 0: Kidney, Right
    Second choice is value 1: Kidney, Left
    Third choice is value 2: Kidneys, Bilateral
  Fifth character (Approach) is value 0: Open
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) is value Z: No Qualifier

FY2024: Second panel of table 0 T T
  Fourth character (Body Part) has 3 choices.
    First choice is value 0: Kidney, Right
    Second choice is value 1: Kidney, Left
    Third choice is value 2: Kidneys, Bilateral
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 2 choices.
    First choice is value G: Hand-Assisted
    Second choice is value Z: No Qualifier

No change: Third panel of table 0 T T
  Fourth character (Body Part) has 7 choices.
    First choice is value 3: Kidney Pelvis, Right
    Second choice is value 4: Kidney Pelvis, Left
    Third choice is value 6: Ureter, Right
    Fourth choice is value 7: Ureter, Left
    Fifth choice is value B: Bladder
    Sixth choice is value C: Bladder Neck
    Seventh choice is value D: Urethra
  Fifth character (Approach) has 4 choices.
    First choice is value 0: Open
    Second choice is value 4: Percutaneous Endoscopic
    Third choice is value 7: Via Natural or Artificial Opening
    Fourth choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) is value Z: No Qualifier

No change: table 0 X 6
  First character (Section) is value 0: Medical and Surgical
  Second character (Body System) is value X: Anatomical Regions, Upper Extremities
  Third character (Operation) is value 6: Detachment: Cutting off all or a portion of the upper or lower extremities

No change: First panel of table 0 X 6
  Fourth character (Body Part) has 6 choices.
    First choice is value 0: Forequarter, Right
    Second choice is value 1: Forequarter, Left
    Third choice is value 2: Shoulder Region, Right
    Fourth choice is value 3: Shoulder Region, Left
    Fifth choice is value B: Elbow Region, Right
    Sixth choice is value C: Elbow Region, Left
  Fifth character (Approach) is value 0: Open
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Second panel of table 0 X 6
  Fourth character (Body Part) has 4 choices.
    First choice is value 8: Upper Arm, Right
    Second choice is value 9: Upper Arm, Left
    Third choice is value D: Lower Arm, Right
    Fourth choice is value F: Lower Arm, Left
  Fifth character (Approach) is value 0: Open
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 3 choices.
    First choice is value 1: High
    Second choice is value 2: Mid
    Third choice is value 3: Low

No change: Third panel of table 0 X 6
  Fourth character (Body Part) has 2 choices.
    First choice is value J: Hand, Right
    Second choice is value K: Hand, Left
  Fifth character (Approach) is value 0: Open
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 11 choices.
    First choice is value 0: Complete
    Second choice is value 4: Complete 1st Ray
    Third choice is value 5: Complete 2nd Ray
    Fourth choice is value 6: Complete 3rd Ray
    Fifth choice is value 7: Complete 4th Ray
    Sixth choice is value 8: Complete 5th Ray
    Seventh choice is value 9: Partial 1st Ray
    Eighth choice is value B: Partial 2nd Ray
    Ninth choice is value C: Partial 3rd Ray
    Tenth choice is value D: Partial 4th Ray
    Eleventh choice is value F: Partial 5th Ray

FY2024: Fourth panel of table 0 X 6
  Fourth character (Body Part) has 2 choices.
    First choice is value L: Thumb, Right
    Second choice is value M: Thumb, Left
  Fifth character (Approach) is value 0: Open
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 3 choices.
    First choice is value 0: Complete
    Second choice is value 1: High
    Third choice is value 3: Low

FY2024: Fifth panel of table 0 X 6
  Fourth character (Body Part) has 8 choices.
    First choice is value N: Index Finger, Right
    Second choice is value P: Index Finger, Left
    Third choice is value Q: Middle Finger, Right
    Fourth choice is value R: Middle Finger, Left
    Fifth choice is value S: Ring Finger, Right
    Sixth choice is value T: Ring Finger, Left
    Seventh choice is value V: Little Finger, Right
    Eighth choice is value W: Little Finger, Left
  Fifth character (Approach) is value 0: Open
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 4 choices.
    First choice is value 0: Complete
    Second choice is value 1: High
    Third choice is value 2: Mid
    Fourth choice is value 3: Low

No change: table 0 Y 6
  First character (Section) is value 0: Medical and Surgical
  Second character (Body System) is value Y: Anatomical Regions, Lower Extremities
  Third character (Operation) is value 6: Detachment: Cutting off all or a portion of the upper or lower extremities

No change: First panel of table 0 Y 6
  Fourth character (Body Part) has 7 choices.
    First choice is value 2: Hindquarter, Right
    Second choice is value 3: Hindquarter, Left
    Third choice is value 4: Hindquarter, Bilateral
    Fourth choice is value 7: Femoral Region, Right
    Fifth choice is value 8: Femoral Region, Left
    Sixth choice is value F: Knee Region, Right
    Seventh choice is value G: Knee Region, Left
  Fifth character (Approach) is value 0: Open
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Second panel of table 0 Y 6
  Fourth character (Body Part) has 4 choices.
    First choice is value C: Upper Leg, Right
    Second choice is value D: Upper Leg, Left
    Third choice is value H: Lower Leg, Right
    Fourth choice is value J: Lower Leg, Left
  Fifth character (Approach) is value 0: Open
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 3 choices.
    First choice is value 1: High
    Second choice is value 2: Mid
    Third choice is value 3: Low

No change: Third panel of table 0 Y 6
  Fourth character (Body Part) has 2 choices.
    First choice is value M: Foot, Right
    Second choice is value N: Foot, Left
  Fifth character (Approach) is value 0: Open
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 11 choices.
    First choice is value 0: Complete
    Second choice is value 4: Complete 1st Ray
    Third choice is value 5: Complete 2nd Ray
    Fourth choice is value 6: Complete 3rd Ray
    Fifth choice is value 7: Complete 4th Ray
    Sixth choice is value 8: Complete 5th Ray
    Seventh choice is value 9: Partial 1st Ray
    Eighth choice is value B: Partial 2nd Ray
    Ninth choice is value C: Partial 3rd Ray
    Tenth choice is value D: Partial 4th Ray
    Eleventh choice is value F: Partial 5th Ray

FY2024: Fourth panel of table 0 Y 6
  Fourth character (Body Part) has 2 choices.
    First choice is value P: 1st Toe, Right
    Second choice is value Q: 1st Toe, Left
  Fifth character (Approach) is value 0: Open
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 3 choices.
    First choice is value 0: Complete
    Second choice is value 1: High
    Third choice is value 3: Low

FY2024: Fifth panel of table 0 Y 6
  Fourth character (Body Part) has 8 choices.
    First choice is value R: 2nd Toe, Right
    Second choice is value S: 2nd Toe, Left
    Third choice is value T: 3rd Toe, Right
    Fourth choice is value U: 3rd Toe, Left
    Fifth choice is value V: 4th Toe, Right
    Sixth choice is value W: 4th Toe, Left
    Seventh choice is value X: 5th Toe, Right
    Eighth choice is value Y: 5th Toe, Left
  Fifth character (Approach) is value 0: Open
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 4 choices.
    First choice is value 0: Complete
    Second choice is value 1: High
    Third choice is value 2: Mid
    Fourth choice is value 3: Low

No change: table 3 E 0
  First character (Section) is value 3: Administration
  Second character (Body System) is value E: Physiological Systems and Anatomical Regions
  Third character (Operation) is value 0: Introduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products

No change: First panel of table 3 E 0
  Fourth character (Body System / Region) is value 0: Skin and Mucous Membranes
  Fifth character (Approach) is value X: External
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 5: Other Antineoplastic
    Second choice is value M: Monoclonal Antibody

No change: Second panel of table 3 E 0
  Fourth character (Body System / Region) is value 0: Skin and Mucous Membranes
  Fifth character (Approach) is value X: External
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Third panel of table 3 E 0
  Fourth character (Body System / Region) is value 0: Skin and Mucous Membranes
  Fifth character (Approach) is value X: External
  Sixth character (Substance) has 7 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 4: Serum, Toxoid and Vaccine
    Third choice is value B: Anesthetic Agent
    Fourth choice is value K: Other Diagnostic Substance
    Fifth choice is value M: Pigment
    Sixth choice is value N: Analgesics, Hypnotics, Sedatives
    Seventh choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value 0: Skin and Mucous Membranes
  Fifth character (Approach) is value X: External
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) is value A: Anti-Infective Envelope

No change: Sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 5: Other Antineoplastic
    Second choice is value M: Monoclonal Antibody

No change: Seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 3 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective
    Third choice is value A: Anti-Infective Envelope

No change: Eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 8 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value N: Analgesics, Hypnotics, Sedatives
    Eighth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 4: Serum, Toxoid and Vaccine
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Influenza Vaccine
    Second choice is value Z: No Qualifier

No change: Tenth panel of table 3 E 0
  Fourth character (Body System / Region) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Eleventh panel of table 3 E 0
  Fourth character (Body System / Region) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value V: Hormone
  Seventh character (Qualifier) has 2 choices.
    First choice is value G: Insulin
    Second choice is value J: Other Hormone

No change: Twelfth panel of table 3 E 0
  Fourth character (Body System / Region) is value 2: Muscle
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 5: Other Antineoplastic
    Second choice is value M: Monoclonal Antibody

No change: Thirteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value 2: Muscle
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Fourteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value 2: Muscle
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 8 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value N: Analgesics, Hypnotics, Sedatives
    Eighth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Fifteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value 2: Muscle
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 4: Serum, Toxoid and Vaccine
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Influenza Vaccine
    Second choice is value Z: No Qualifier

No change: Sixteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value 2: Muscle
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Seventeenth panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 5 choices.
    First choice is value 2: High-dose Interleukin-2
    Second choice is value 3: Low-dose Interleukin-2
    Third choice is value 5: Other Antineoplastic
    Fourth choice is value M: Monoclonal Antibody
    Fifth choice is value P: Clofarabine

No change: Eighteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value 1: Thrombolytic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 6: Recombinant Human-activated Protein C
    Second choice is value 7: Other Thrombolytic

No change: Nineteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Twentieth panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) has 12 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 4: Serum, Toxoid and Vaccine
    Third choice is value 6: Nutritional Substance
    Fourth choice is value 7: Electrolytic and Water Balance Substance
    Fifth choice is value F: Intracirculatory Anesthetic
    Sixth choice is value H: Radioactive Substance
    Seventh choice is value K: Other Diagnostic Substance
    Eighth choice is value N: Analgesics, Hypnotics, Sedatives
    Ninth choice is value P: Platelet Inhibitor
    Tenth choice is value R: Antiarrhythmic
    Eleventh choice is value T: Destructive Agent
    Twelfth choice is value X: Vasopressor
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Twenty-first panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) has 2 choices.
    First choice is value C: Other Substance
    Second choice is value N: Blood Brain Barrier Disruption

No change: Twenty-second panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value U: Pancreatic Islet Cells
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Autologous
    Second choice is value 1: Nonautologous

No change: Twenty-third panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value V: Hormone
  Seventh character (Qualifier) has 3 choices.
    First choice is value G: Insulin
    Second choice is value H: Human B-type Natriuretic Peptide
    Third choice is value J: Other Hormone

No change: Twenty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value W: Immunotherapeutic
  Seventh character (Qualifier) has 2 choices.
    First choice is value K: Immunostimulator
    Second choice is value L: Immunosuppressive

No change: Twenty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 5 choices.
    First choice is value 2: High-dose Interleukin-2
    Second choice is value 3: Low-dose Interleukin-2
    Third choice is value 5: Other Antineoplastic
    Fourth choice is value M: Monoclonal Antibody
    Fifth choice is value P: Clofarabine

No change: Twenty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 1: Thrombolytic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 6: Recombinant Human-activated Protein C
    Second choice is value 7: Other Thrombolytic

No change: Twenty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Twenty-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 12 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 4: Serum, Toxoid and Vaccine
    Third choice is value 6: Nutritional Substance
    Fourth choice is value 7: Electrolytic and Water Balance Substance
    Fifth choice is value F: Intracirculatory Anesthetic
    Sixth choice is value H: Radioactive Substance
    Seventh choice is value K: Other Diagnostic Substance
    Eighth choice is value N: Analgesics, Hypnotics, Sedatives
    Ninth choice is value P: Platelet Inhibitor
    Tenth choice is value R: Antiarrhythmic
    Eleventh choice is value T: Destructive Agent
    Twelfth choice is value X: Vasopressor
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Twenty-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) has 4 choices.
    First choice is value C: Other Substance
    Second choice is value N: Blood Brain Barrier Disruption
    Third choice is value Q: Glucarpidase
    Fourth choice is value R: Other Therapeutic Monoclonal Antibody

No change: Thirtieth panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value U: Pancreatic Islet Cells
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Autologous
    Second choice is value 1: Nonautologous

No change: Thirty-first panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value V: Hormone
  Seventh character (Qualifier) has 3 choices.
    First choice is value G: Insulin
    Second choice is value H: Human B-type Natriuretic Peptide
    Third choice is value J: Other Hormone

No change: Thirty-second panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value W: Immunotherapeutic
  Seventh character (Qualifier) has 2 choices.
    First choice is value K: Immunostimulator
    Second choice is value L: Immunosuppressive

No change: Thirty-third panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 5 choices.
    First choice is value 2: High-dose Interleukin-2
    Second choice is value 3: Low-dose Interleukin-2
    Third choice is value 5: Other Antineoplastic
    Fourth choice is value M: Monoclonal Antibody
    Fifth choice is value P: Clofarabine

No change: Thirty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value 1: Thrombolytic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 6: Recombinant Human-activated Protein C
    Second choice is value 7: Other Thrombolytic

No change: Thirty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Thirty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) has 12 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 4: Serum, Toxoid and Vaccine
    Third choice is value 6: Nutritional Substance
    Fourth choice is value 7: Electrolytic and Water Balance Substance
    Fifth choice is value F: Intracirculatory Anesthetic
    Sixth choice is value H: Radioactive Substance
    Seventh choice is value K: Other Diagnostic Substance
    Eighth choice is value N: Analgesics, Hypnotics, Sedatives
    Ninth choice is value P: Platelet Inhibitor
    Tenth choice is value R: Antiarrhythmic
    Eleventh choice is value T: Destructive Agent
    Twelfth choice is value X: Vasopressor
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Thirty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) has 2 choices.
    First choice is value C: Other Substance
    Second choice is value N: Blood Brain Barrier Disruption

No change: Thirty-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value V: Hormone
  Seventh character (Qualifier) has 3 choices.
    First choice is value G: Insulin
    Second choice is value H: Human B-type Natriuretic Peptide
    Third choice is value J: Other Hormone

No change: Thirty-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value W: Immunotherapeutic
  Seventh character (Qualifier) has 2 choices.
    First choice is value K: Immunostimulator
    Second choice is value L: Immunosuppressive

No change: Fortieth panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 5 choices.
    First choice is value 2: High-dose Interleukin-2
    Second choice is value 3: Low-dose Interleukin-2
    Third choice is value 5: Other Antineoplastic
    Fourth choice is value M: Monoclonal Antibody
    Fifth choice is value P: Clofarabine

No change: Forty-first panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 1: Thrombolytic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 6: Recombinant Human-activated Protein C
    Second choice is value 7: Other Thrombolytic

No change: Forty-second panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Forty-third panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 12 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 4: Serum, Toxoid and Vaccine
    Third choice is value 6: Nutritional Substance
    Fourth choice is value 7: Electrolytic and Water Balance Substance
    Fifth choice is value F: Intracirculatory Anesthetic
    Sixth choice is value H: Radioactive Substance
    Seventh choice is value K: Other Diagnostic Substance
    Eighth choice is value N: Analgesics, Hypnotics, Sedatives
    Ninth choice is value P: Platelet Inhibitor
    Tenth choice is value R: Antiarrhythmic
    Eleventh choice is value T: Destructive Agent
    Twelfth choice is value X: Vasopressor
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Forty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) has 4 choices.
    First choice is value C: Other Substance
    Second choice is value N: Blood Brain Barrier Disruption
    Third choice is value Q: Glucarpidase
    Fourth choice is value R: Other Therapeutic Monoclonal Antibody

No change: Forty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value V: Hormone
  Seventh character (Qualifier) has 3 choices.
    First choice is value G: Insulin
    Second choice is value H: Human B-type Natriuretic Peptide
    Third choice is value J: Other Hormone

No change: Forty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value W: Immunotherapeutic
  Seventh character (Qualifier) has 2 choices.
    First choice is value K: Immunostimulator
    Second choice is value L: Immunosuppressive

No change: Forty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 5: Peripheral Artery
    Second choice is value 6: Central Artery
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 5 choices.
    First choice is value 2: High-dose Interleukin-2
    Second choice is value 3: Low-dose Interleukin-2
    Third choice is value 5: Other Antineoplastic
    Fourth choice is value M: Monoclonal Antibody
    Fifth choice is value P: Clofarabine

No change: Forty-eighth panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 5: Peripheral Artery
    Second choice is value 6: Central Artery
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value 1: Thrombolytic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 6: Recombinant Human-activated Protein C
    Second choice is value 7: Other Thrombolytic

No change: Forty-ninth panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 5: Peripheral Artery
    Second choice is value 6: Central Artery
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Fiftieth panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 5: Peripheral Artery
    Second choice is value 6: Central Artery
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) has 12 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 4: Serum, Toxoid and Vaccine
    Third choice is value 6: Nutritional Substance
    Fourth choice is value 7: Electrolytic and Water Balance Substance
    Fifth choice is value F: Intracirculatory Anesthetic
    Sixth choice is value H: Radioactive Substance
    Seventh choice is value K: Other Diagnostic Substance
    Eighth choice is value N: Analgesics, Hypnotics, Sedatives
    Ninth choice is value P: Platelet Inhibitor
    Tenth choice is value R: Antiarrhythmic
    Eleventh choice is value T: Destructive Agent
    Twelfth choice is value X: Vasopressor
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Fifty-first panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 5: Peripheral Artery
    Second choice is value 6: Central Artery
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) has 2 choices.
    First choice is value C: Other Substance
    Second choice is value N: Blood Brain Barrier Disruption

No change: Fifty-second panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 5: Peripheral Artery
    Second choice is value 6: Central Artery
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value V: Hormone
  Seventh character (Qualifier) has 3 choices.
    First choice is value G: Insulin
    Second choice is value H: Human B-type Natriuretic Peptide
    Third choice is value J: Other Hormone

No change: Fifty-third panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 5: Peripheral Artery
    Second choice is value 6: Central Artery
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value W: Immunotherapeutic
  Seventh character (Qualifier) has 2 choices.
    First choice is value K: Immunostimulator
    Second choice is value L: Immunosuppressive

No change: Fifty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 7: Coronary Artery
    Second choice is value 8: Heart
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value 1: Thrombolytic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 6: Recombinant Human-activated Protein C
    Second choice is value 7: Other Thrombolytic

No change: Fifty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 7: Coronary Artery
    Second choice is value 8: Heart
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Fifty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 7: Coronary Artery
    Second choice is value 8: Heart
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) has 2 choices.
    First choice is value K: Other Diagnostic Substance
    Second choice is value P: Platelet Inhibitor
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Fifty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 7: Coronary Artery
    Second choice is value 8: Heart
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Fifty-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value 9: Nose
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 5: Other Antineoplastic
    Second choice is value M: Monoclonal Antibody

No change: Fifty-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value 9: Nose
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Sixtieth panel of table 3 E 0
  Fourth character (Body System / Region) is value 9: Nose
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) has 7 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 4: Serum, Toxoid and Vaccine
    Third choice is value B: Anesthetic Agent
    Fourth choice is value H: Radioactive Substance
    Fifth choice is value K: Other Diagnostic Substance
    Sixth choice is value N: Analgesics, Hypnotics, Sedatives
    Seventh choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Sixty-first panel of table 3 E 0
  Fourth character (Body System / Region) is value 9: Nose
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Sixty-second panel of table 3 E 0
  Fourth character (Body System / Region) is value A: Bone Marrow
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 5: Other Antineoplastic
    Second choice is value M: Monoclonal Antibody

No change: Sixty-third panel of table 3 E 0
  Fourth character (Body System / Region) is value A: Bone Marrow
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Sixty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value B: Ear
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: Sixty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value B: Ear
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Sixty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value B: Ear
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) has 6 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value B: Anesthetic Agent
    Third choice is value H: Radioactive Substance
    Fourth choice is value K: Other Diagnostic Substance
    Fifth choice is value N: Analgesics, Hypnotics, Sedatives
    Sixth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Sixty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value B: Ear
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Sixty-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value C: Eye
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: Sixty-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value C: Eye
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Seventieth panel of table 3 E 0
  Fourth character (Body System / Region) is value C: Eye
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) has 7 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value B: Anesthetic Agent
    Third choice is value H: Radioactive Substance
    Fourth choice is value K: Other Diagnostic Substance
    Fifth choice is value M: Pigment
    Sixth choice is value N: Analgesics, Hypnotics, Sedatives
    Seventh choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Seventy-first panel of table 3 E 0
  Fourth character (Body System / Region) is value C: Eye
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Seventy-second panel of table 3 E 0
  Fourth character (Body System / Region) is value C: Eye
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: Seventy-third panel of table 3 E 0
  Fourth character (Body System / Region) is value D: Mouth and Pharynx
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: Seventy-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value D: Mouth and Pharynx
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Seventy-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value D: Mouth and Pharynx
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) has 10 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 4: Serum, Toxoid and Vaccine
    Third choice is value 6: Nutritional Substance
    Fourth choice is value 7: Electrolytic and Water Balance Substance
    Fifth choice is value B: Anesthetic Agent
    Sixth choice is value H: Radioactive Substance
    Seventh choice is value K: Other Diagnostic Substance
    Eighth choice is value N: Analgesics, Hypnotics, Sedatives
    Ninth choice is value R: Antiarrhythmic
    Tenth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Seventy-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value D: Mouth and Pharynx
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Seventy-seventh panel of table 3 E 0
  Fourth character (Body System / Region) has 5 choices.
    First choice is value E: Products of Conception
    Second choice is value G: Upper GI
    Third choice is value H: Lower GI
    Fourth choice is value K: Genitourinary Tract
    Fifth choice is value N: Male Reproductive
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: Seventy-eighth panel of table 3 E 0
  Fourth character (Body System / Region) has 5 choices.
    First choice is value E: Products of Conception
    Second choice is value G: Upper GI
    Third choice is value H: Lower GI
    Fourth choice is value K: Genitourinary Tract
    Fifth choice is value N: Male Reproductive
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Seventy-ninth panel of table 3 E 0
  Fourth character (Body System / Region) has 5 choices.
    First choice is value E: Products of Conception
    Second choice is value G: Upper GI
    Third choice is value H: Lower GI
    Fourth choice is value K: Genitourinary Tract
    Fifth choice is value N: Male Reproductive
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) has 8 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value N: Analgesics, Hypnotics, Sedatives
    Eighth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Eightieth panel of table 3 E 0
  Fourth character (Body System / Region) has 5 choices.
    First choice is value E: Products of Conception
    Second choice is value G: Upper GI
    Third choice is value H: Lower GI
    Fourth choice is value K: Genitourinary Tract
    Fifth choice is value N: Male Reproductive
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Eighty-first panel of table 3 E 0
  Fourth character (Body System / Region) has 5 choices.
    First choice is value E: Products of Conception
    Second choice is value G: Upper GI
    Third choice is value H: Lower GI
    Fourth choice is value K: Genitourinary Tract
    Fifth choice is value N: Male Reproductive
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: Eighty-second panel of table 3 E 0
  Fourth character (Body System / Region) has 5 choices.
    First choice is value E: Products of Conception
    Second choice is value G: Upper GI
    Third choice is value H: Lower GI
    Fourth choice is value K: Genitourinary Tract
    Fifth choice is value N: Male Reproductive
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Eighty-third panel of table 3 E 0
  Fourth character (Body System / Region) is value F: Respiratory Tract
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: Eighty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value F: Respiratory Tract
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Eighty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value F: Respiratory Tract
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) has 8 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value N: Analgesics, Hypnotics, Sedatives
    Eighth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Eighty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value F: Respiratory Tract
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Eighty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value F: Respiratory Tract
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) has 2 choices.
    First choice is value D: Nitric Oxide
    Second choice is value F: Other Gas

No change: Eighty-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value F: Respiratory Tract
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Eighty-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value J: Biliary and Pancreatic Tract
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: Ninetieth panel of table 3 E 0
  Fourth character (Body System / Region) is value J: Biliary and Pancreatic Tract
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Ninety-first panel of table 3 E 0
  Fourth character (Body System / Region) is value J: Biliary and Pancreatic Tract
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) has 8 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value N: Analgesics, Hypnotics, Sedatives
    Eighth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Ninety-second panel of table 3 E 0
  Fourth character (Body System / Region) is value J: Biliary and Pancreatic Tract
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Ninety-third panel of table 3 E 0
  Fourth character (Body System / Region) is value J: Biliary and Pancreatic Tract
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: Ninety-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value J: Biliary and Pancreatic Tract
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value U: Pancreatic Islet Cells
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Autologous
    Second choice is value 1: Nonautologous

No change: Ninety-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value J: Biliary and Pancreatic Tract
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Ninety-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value L: Pleural Cavity
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value 5: Adhesion Barrier
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Ninety-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value L: Pleural Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

FY2024: Ninety-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value L: Pleural Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 1: Thrombolytic
  Seventh character (Qualifier) is value 7: Other Thrombolytic

No change: Ninety-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value L: Pleural Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundredth panel of table 3 E 0
  Fourth character (Body System / Region) is value L: Pleural Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 9 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 5: Adhesion Barrier
    Third choice is value 6: Nutritional Substance
    Fourth choice is value 7: Electrolytic and Water Balance Substance
    Fifth choice is value B: Anesthetic Agent
    Sixth choice is value H: Radioactive Substance
    Seventh choice is value K: Other Diagnostic Substance
    Eighth choice is value N: Analgesics, Hypnotics, Sedatives
    Ninth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred First panel of table 3 E 0
  Fourth character (Body System / Region) is value L: Pleural Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Second panel of table 3 E 0
  Fourth character (Body System / Region) is value L: Pleural Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Third panel of table 3 E 0
  Fourth character (Body System / Region) is value L: Pleural Cavity
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value 5: Adhesion Barrier
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value L: Pleural Cavity
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value L: Pleural Cavity
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: One hundred Sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value L: Pleural Cavity
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value M: Peritoneal Cavity
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value 5: Adhesion Barrier
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value M: Peritoneal Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 4 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody
    Fourth choice is value Y: Hyperthermic

No change: One hundred Ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value M: Peritoneal Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred Tenth panel of table 3 E 0
  Fourth character (Body System / Region) is value M: Peritoneal Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 9 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 5: Adhesion Barrier
    Third choice is value 6: Nutritional Substance
    Fourth choice is value 7: Electrolytic and Water Balance Substance
    Fifth choice is value B: Anesthetic Agent
    Sixth choice is value H: Radioactive Substance
    Seventh choice is value K: Other Diagnostic Substance
    Eighth choice is value N: Analgesics, Hypnotics, Sedatives
    Ninth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Eleventh panel of table 3 E 0
  Fourth character (Body System / Region) is value M: Peritoneal Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Twelfth panel of table 3 E 0
  Fourth character (Body System / Region) is value M: Peritoneal Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Thirteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value M: Peritoneal Cavity
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value 5: Adhesion Barrier
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Fourteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value M: Peritoneal Cavity
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Fifteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value M: Peritoneal Cavity
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: One hundred Sixteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value M: Peritoneal Cavity
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Seventeenth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value 5: Adhesion Barrier
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Eighteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: One hundred Nineteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred Twentieth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 11 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 5: Adhesion Barrier
    Third choice is value 6: Nutritional Substance
    Fourth choice is value 7: Electrolytic and Water Balance Substance
    Fifth choice is value B: Anesthetic Agent
    Sixth choice is value H: Radioactive Substance
    Seventh choice is value K: Other Diagnostic Substance
    Eighth choice is value L: Sperm
    Ninth choice is value N: Analgesics, Hypnotics, Sedatives
    Tenth choice is value T: Destructive Agent
    Eleventh choice is value V: Hormone
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Twenty-first panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Twenty-second panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value Q: Fertilized Ovum
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Autologous
    Second choice is value 1: Nonautologous

No change: One hundred Twenty-third panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Twenty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value 5: Adhesion Barrier
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Twenty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Twenty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: One hundred Twenty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred Twenty-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) has 10 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value L: Sperm
    Eighth choice is value N: Analgesics, Hypnotics, Sedatives
    Ninth choice is value T: Destructive Agent
    Tenth choice is value V: Hormone
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Twenty-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Thirtieth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value Q: Fertilized Ovum
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Autologous
    Second choice is value 1: Nonautologous

No change: One hundred Thirty-first panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Thirty-second panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: One hundred Thirty-third panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred Thirty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) has 8 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value N: Analgesics, Hypnotics, Sedatives
    Eighth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Thirty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Thirty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Thirty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value Q: Cranial Cavity and Brain
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: One hundred Thirty-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value Q: Cranial Cavity and Brain
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred Thirty-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value Q: Cranial Cavity and Brain
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) has 9 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value A: Stem Cells, Embryonic
    Fifth choice is value B: Anesthetic Agent
    Sixth choice is value H: Radioactive Substance
    Seventh choice is value K: Other Diagnostic Substance
    Eighth choice is value N: Analgesics, Hypnotics, Sedatives
    Ninth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Fortieth panel of table 3 E 0
  Fourth character (Body System / Region) is value Q: Cranial Cavity and Brain
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value E: Stem Cells, Somatic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Autologous
    Second choice is value 1: Nonautologous

No change: One hundred Forty-first panel of table 3 E 0
  Fourth character (Body System / Region) is value Q: Cranial Cavity and Brain
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Forty-second panel of table 3 E 0
  Fourth character (Body System / Region) is value Q: Cranial Cavity and Brain
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Forty-third panel of table 3 E 0
  Fourth character (Body System / Region) is value Q: Cranial Cavity and Brain
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: One hundred Forty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value Q: Cranial Cavity and Brain
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Forty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value R: Spinal Canal
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value A: Stem Cells, Embryonic
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Forty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value R: Spinal Canal
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value E: Stem Cells, Somatic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Autologous
    Second choice is value 1: Nonautologous

No change: One hundred Forty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value R: Spinal Canal
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 5 choices.
    First choice is value 2: High-dose Interleukin-2
    Second choice is value 3: Low-dose Interleukin-2
    Third choice is value 4: Liquid Brachytherapy Radioisotope
    Fourth choice is value 5: Other Antineoplastic
    Fifth choice is value M: Monoclonal Antibody

No change: One hundred Forty-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value R: Spinal Canal
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred Forty-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value R: Spinal Canal
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 9 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value A: Stem Cells, Embryonic
    Fifth choice is value B: Anesthetic Agent
    Sixth choice is value H: Radioactive Substance
    Seventh choice is value K: Other Diagnostic Substance
    Eighth choice is value N: Analgesics, Hypnotics, Sedatives
    Ninth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Fiftieth panel of table 3 E 0
  Fourth character (Body System / Region) is value R: Spinal Canal
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value E: Stem Cells, Somatic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Autologous
    Second choice is value 1: Nonautologous

No change: One hundred Fifty-first panel of table 3 E 0
  Fourth character (Body System / Region) is value R: Spinal Canal
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Fifty-second panel of table 3 E 0
  Fourth character (Body System / Region) is value R: Spinal Canal
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Fifty-third panel of table 3 E 0
  Fourth character (Body System / Region) is value R: Spinal Canal
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Fifty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value S: Epidural Space
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 5 choices.
    First choice is value 2: High-dose Interleukin-2
    Second choice is value 3: Low-dose Interleukin-2
    Third choice is value 4: Liquid Brachytherapy Radioisotope
    Fourth choice is value 5: Other Antineoplastic
    Fifth choice is value M: Monoclonal Antibody

No change: One hundred Fifty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value S: Epidural Space
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred Fifty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value S: Epidural Space
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 8 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value N: Analgesics, Hypnotics, Sedatives
    Eighth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Fifty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value S: Epidural Space
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Fifty-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value S: Epidural Space
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Fifty-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value S: Epidural Space
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Sixtieth panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value T: Peripheral Nerves and Plexi
    Second choice is value X: Cranial Nerves
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 3 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value B: Anesthetic Agent
    Third choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Sixty-first panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value T: Peripheral Nerves and Plexi
    Second choice is value X: Cranial Nerves
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Sixty-second panel of table 3 E 0
  Fourth character (Body System / Region) is value U: Joints
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred Sixty-third panel of table 3 E 0
  Fourth character (Body System / Region) is value U: Joints
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value B: Recombinant Bone Morphogenetic Protein

No change: One hundred Sixty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value U: Joints
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: One hundred Sixty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value U: Joints
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred Sixty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value U: Joints
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 8 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value N: Analgesics, Hypnotics, Sedatives
    Eighth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Sixty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value U: Joints
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) has 2 choices.
    First choice is value B: Recombinant Bone Morphogenetic Protein
    Second choice is value C: Other Substance

No change: One hundred Sixty-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value U: Joints
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Sixty-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value U: Joints
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Seventieth panel of table 3 E 0
  Fourth character (Body System / Region) is value V: Bones
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) has 2 choices.
    First choice is value B: Recombinant Bone Morphogenetic Protein
    Second choice is value C: Other Substance

No change: One hundred Seventy-first panel of table 3 E 0
  Fourth character (Body System / Region) is value V: Bones
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 5: Other Antineoplastic
    Second choice is value M: Monoclonal Antibody

No change: One hundred Seventy-second panel of table 3 E 0
  Fourth character (Body System / Region) is value V: Bones
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred Seventy-third panel of table 3 E 0
  Fourth character (Body System / Region) is value V: Bones
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 8 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value N: Analgesics, Hypnotics, Sedatives
    Eighth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Seventy-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value V: Bones
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) has 2 choices.
    First choice is value B: Recombinant Bone Morphogenetic Protein
    Second choice is value C: Other Substance

No change: One hundred Seventy-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value V: Bones
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Seventy-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value W: Lymphatics
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 5: Other Antineoplastic
    Second choice is value M: Monoclonal Antibody

No change: One hundred Seventy-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value W: Lymphatics
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred Seventy-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value W: Lymphatics
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 8 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value N: Analgesics, Hypnotics, Sedatives
    Eighth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Seventy-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value W: Lymphatics
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Eightieth panel of table 3 E 0
  Fourth character (Body System / Region) is value Y: Pericardial Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: One hundred Eighty-first panel of table 3 E 0
  Fourth character (Body System / Region) is value Y: Pericardial Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred Eighty-second panel of table 3 E 0
  Fourth character (Body System / Region) is value Y: Pericardial Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 8 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value N: Analgesics, Hypnotics, Sedatives
    Eighth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Eighty-third panel of table 3 E 0
  Fourth character (Body System / Region) is value Y: Pericardial Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Eighty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value Y: Pericardial Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Eighty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value Y: Pericardial Cavity
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Eighty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value Y: Pericardial Cavity
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: One hundred Eighty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value Y: Pericardial Cavity
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: table 5 A 0
  First character (Section) is value 5: Extracorporeal or Systemic Assistance and Performance
  Second character (Body System) is value A: Physiological Systems
  Third character (Operation) is value 0: Assistance: Taking over a portion of a physiological function by extracorporeal means

No change: First panel of table 5 A 0
  Fourth character (Body System) is value 2: Cardiac
  Fifth character (Duration) is value 1: Intermittent
  Sixth character (Function) is value 1: Output
  Seventh character (Qualifier) has 4 choices.
    First choice is value 0: Balloon Pump
    Second choice is value 5: Pulsatile Compression
    Third choice is value 6: Other Pump
    Fourth choice is value D: Impeller Pump

No change: Second panel of table 5 A 0
  Fourth character (Body System) is value 2: Cardiac
  Fifth character (Duration) is value 2: Continuous
  Sixth character (Function) is value 1: Output
  Seventh character (Qualifier) has 4 choices.
    First choice is value 0: Balloon Pump
    Second choice is value 5: Pulsatile Compression
    Third choice is value 6: Other Pump
    Fourth choice is value D: Impeller Pump

No change: Third panel of table 5 A 0
  Fourth character (Body System) is value 2: Cardiac
  Fifth character (Duration) is value 2: Continuous
  Sixth character (Function) is value 2: Oxygenation
  Seventh character (Qualifier) is value C: Supersaturated

No change: Fourth panel of table 5 A 0
  Fourth character (Body System) is value 5: Circulatory
  Fifth character (Duration) has 2 choices.
    First choice is value 1: Intermittent
    Second choice is value 2: Continuous
  Sixth character (Function) is value 2: Oxygenation
  Seventh character (Qualifier) is value 1: Hyperbaric

No change: Fifth panel of table 5 A 0
  Fourth character (Body System) is value 9: Respiratory
  Fifth character (Duration) is value 2: Continuous
  Sixth character (Function) is value 0: Filtration
  Seventh character (Qualifier) is value Z: No Qualifier

Revise from: Sixth panel of table 5 A 0
  Fourth character (Body System) is value 9: Respiratory
  Fifth character (Duration) has 3 choices.
    First choice is value 3: Less than 24 Consecutive Hours
    Second choice is value 4: 24-96 Consecutive Hours
    Third choice is value 5: Greater than 96 Consecutive Hours
  Sixth character (Function) is value 5: Ventilation
  Seventh character (Qualifier) has 6 choices.
    First choice is value 7: Continuous Positive Airway Pressure
    Second choice is value 8: Intermittent Positive Airway Pressure
    Third choice is value 9: Continuous Negative Airway Pressure
    Fourth choice is value A: High Nasal Flow/Velocity
    Fifth choice is value B: Intermittent Negative Airway Pressure
    Sixth choice is value Z: No Qualifier

Revise to: Sixth panel of table 5 A 0
  Fourth character (Body System) is value 9: Respiratory
  Fifth character (Duration) has 3 choices.
    First choice is value 3: Less than 24 Consecutive Hours
    Second choice is value 4: 24-96 Consecutive Hours
    Third choice is value 5: Greater than 96 Consecutive Hours
  Sixth character (Function) is value 5: Ventilation
  Seventh character (Qualifier) has 6 choices.
    First choice is value 7: Continuous Positive Airway Pressure
    Second choice is value 8: Intermittent Positive Airway Pressure
    Third choice is value 9: Continuous Negative Airway Pressure
    Fourth choice is value A: High Flow/Velocity Cannula
    Fifth choice is value B: Intermittent Negative Airway Pressure
    Sixth choice is value Z: No Qualifier

No change: Seventh panel of table 5 A 0
  Fourth character (Body System) is value 9: Respiratory
  Fifth character (Duration) has 3 choices.
    First choice is value B: Less than 8 Consecutive Hours
    Second choice is value C: 8-24 Consecutive Hours
    Third choice is value D: Greater than 24 Consecutive Hours
  Sixth character (Function) is value 5: Ventilation
  Seventh character (Qualifier) is value K: Intubated Prone Positioning

FY2024: table G Z B
  First character (Section) is value G: Mental Health
  Second character (Body System) is value Z: None
  Third character (Type) is value B: Electroconvulsive Therapy: The application of controlled electrical voltages to treat a mental health disorder

FY2024: First panel of table G Z B
  Fourth character (Qualifier) has 3 choices.
    First choice is value 0: Unilateral-Single Seizure
    Second choice is value 2: Bilateral-Single Seizure
    Third choice is value 4: Other Electroconvulsive Therapy
  Fifth character (Qualifier) is value Z: None
  Sixth character (Qualifier) is value Z: None
  Seventh character (Qualifier) is value Z: None

No change: table X W 0
  First character (Section) is value X: New Technology
  Second character (Body System) is value W: Anatomical Regions
  Third character (Operation) is value 0: Introduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products

No change: First panel of table X W 0
  Fourth character (Body Part) is value 0: Skin
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value 2: Anacaulase-bcdb
  Seventh character (Qualifier) is value 7: New Technology Group 7

FY2024: Second panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 1: Daratumumab and Hyaluronidase-fihj
  Seventh character (Qualifier) is value 8: New Technology Group 8

FY2024: Third panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 2: Talquetamab Antineoplastic
  Seventh character (Qualifier) is value 9: New Technology Group 9

FY2024: Fourth panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 4: Teclistamab Antineoplastic
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Fifth panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 9: Satralizumab-mwge
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Sixth panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value F: Other New Technology Therapeutic Substance
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Seventh panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 3 choices.
    First choice is value G: REGN-COV2 Monoclonal Antibody
    Second choice is value H: Other New Technology Monoclonal Antibody
    Third choice is value K: Leronlimab Monoclonal Antibody
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Eighth panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value L: Elranatamab Antineoplastic
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: Ninth panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value S: COVID-19 Vaccine Dose 1
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Tenth panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value S: Epcoritamab Monoclonal Antibody
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: Eleventh panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value T: COVID-19 Vaccine Dose 2
    Second choice is value U: COVID-19 Vaccine
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Twelfth panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value V: COVID-19 Vaccine Dose 3
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Thirteenth panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value W: Caplacizumab
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Fourteenth panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value W: COVID-19 Vaccine Booster
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Fifteenth panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value 2: Anacaulase-bcdb
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Sixteenth panel of table X W 0
  Fourth character (Body Part) is value 2: Muscle
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value D: Engineered Allogeneic Thymus Tissue
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Seventeenth panel of table X W 0
  Fourth character (Body Part) is value 2: Muscle
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 3 choices.
    First choice is value S: COVID-19 Vaccine Dose 1
    Second choice is value T: COVID-19 Vaccine Dose 2
    Third choice is value U: COVID-19 Vaccine
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Eighteenth panel of table X W 0
  Fourth character (Body Part) is value 2: Muscle
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 4 choices.
    First choice is value V: COVID-19 Vaccine Dose 3
    Second choice is value W: COVID-19 Vaccine Booster
    Third choice is value X: Tixagevimab and Cilgavimab Monoclonal Antibody
    Fourth choice is value Y: Other New Technology Monoclonal Antibody
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Nineteenth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 0: Brexanolone
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Twentieth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 0: Spesolimab Monoclonal Antibody
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Twenty-first panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value 2: Nerinitide
    Second choice is value 3: Durvalumab Antineoplastic
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Twenty-second panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 5: Narsoplimab Monoclonal Antibody
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Twenty-third panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 5: Mosunetuzumab Antineoplastic
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Twenty-fourth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 6: Lefamulin Anti-infective
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Twenty-fifth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 6: Terlipressin
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Twenty-sixth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 6: Afamitresgene Autoleucel Immunotherapy
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Twenty-seventh panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 7: Coagulation Factor Xa, Inactivated
  Seventh character (Qualifier) is value 2: New Technology Group 2

No change: Twenty-eighth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 7: Trilaciclib
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Twenty-ninth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 7: Tabelecleucel Immunotherapy
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Thirtieth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 8: Lurbinectedin
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Thirty-first panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 8: Treosulfan
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Thirty-second panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 9: Ceftolozane/Tazobactam Anti-infective
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Thirty-third panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 9: Inebilizumab-cdon
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Thirty-fourth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value A: Cefiderocol Anti-infective
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Thirty-fifth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value A: Ciltacabtagene Autoleucel
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Thirty-sixth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value B: Cytarabine and Daunorubicin Liposome Antineoplastic
  Seventh character (Qualifier) is value 3: New Technology Group 3

No change: Thirty-seventh panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value B: Omadacycline Anti-infective
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Thirty-eighth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value B: Amivantamab Monoclonal Antibody
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Thirty-ninth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value C: Eculizumab
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Fortieth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value C: Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Forty-first panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value D: Atezolizumab Antineoplastic
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Forty-second panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value E: Remdesivir Anti-infective
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Forty-third panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value E: Etesevimab Monoclonal Antibody
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Forty-fourth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value F: Other New Technology Therapeutic Substance
  Seventh character (Qualifier) is value 3: New Technology Group 3

No change: Forty-fifth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value F: Other New Technology Therapeutic Substance
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Forty-sixth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value F: Bamlanivimab Monoclonal Antibody
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Forty-seventh panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value G: Sarilumab
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Forty-eighth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value G: REGN-COV2 Monoclonal Antibody
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Forty-ninth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value G: Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Fiftieth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value H: Tocilizumab
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Fifty-first panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value H: Other New Technology Monoclonal Antibody
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Fifty-second panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value H: Axicabtagene Ciloleucel Immunotherapy
    Second choice is value J: Tisagenlecleucel Immunotherapy
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Fifty-third panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value K: Fosfomycin Anti-infective
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Fifty-fourth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value K: Idecabtagene Vicleucel Immunotherapy
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Fifty-fifth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value K: Sulbactam-Durlobactam
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: Fifty-sixth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value L: CD24Fc Immunomodulator
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Fifty-seventh panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value L: Lifileucel Immunotherapy
    Second choice is value M: Brexucabtagene Autoleucel Immunotherapy
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Fifty-eighth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value N: Meropenem-vaborbactam Anti-infective
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Fifty-ninth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value N: Lisocabtagene Maraleucel Immunotherapy
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Sixtieth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value P: Glofitamab Antineoplastic
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: Sixty-first panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value Q: Tagraxofusp-erzs Antineoplastic
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Sixty-second panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value Q: Posoleucel
    Second choice is value R: Rezafungin
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: Sixty-third panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 3 choices.
    First choice is value S: Iobenguane I-131 Antineoplastic
    Second choice is value U: Imipenem-cilastatin-relebactam Anti-infective
    Third choice is value W: Caplacizumab
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Sixty-fourth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 0: Brexanolone
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Sixty-fifth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 0: Spesolimab Monoclonal Antibody
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Sixty-sixth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value 2: Nerinitide
    Second choice is value 3: Durvalumab Antineoplastic
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Sixty-seventh panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 5: Narsoplimab Monoclonal Antibody
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Sixty-eighth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 5: Mosunetuzumab Antineoplastic
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Sixty-ninth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 6: Lefamulin Anti-infective
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Seventieth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 6: Terlipressin
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Seventy-first panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 6: Afamitresgene Autoleucel Immunotherapy
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Seventy-second panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 7: Coagulation Factor Xa, Inactivated
  Seventh character (Qualifier) is value 2: New Technology Group 2

No change: Seventy-third panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 7: Trilaciclib
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Seventy-fourth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 7: Tabelecleucel Immunotherapy
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Seventy-fifth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 8: Lurbinectedin
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Seventy-sixth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 8: Treosulfan
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Seventy-seventh panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 9: Ceftolozane/Tazobactam Anti-infective
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Seventy-eighth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 9: Inebilizumab-cdon
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Seventy-ninth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value A: Cefiderocol Anti-infective
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Eightieth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value A: Ciltacabtagene Autoleucel
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Eighty-first panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value B: Cytarabine and Daunorubicin Liposome Antineoplastic
  Seventh character (Qualifier) is value 3: New Technology Group 3

No change: Eighty-second panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value B: Omadacycline Anti-infective
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Eighty-third panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value B: Amivantamab Monoclonal Antibody
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Eighty-fourth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value C: Eculizumab
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Eighty-fifth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value C: Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Eighty-sixth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value D: Atezolizumab Antineoplastic
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Eighty-seventh panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value E: Remdesivir Anti-infective
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Eighty-eighth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value E: Etesevimab Monoclonal Antibody
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Eighty-ninth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value F: Other New Technology Therapeutic Substance
  Seventh character (Qualifier) is value 3: New Technology Group 3

No change: Ninetieth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value F: Other New Technology Therapeutic Substance
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Ninety-first panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value F: Bamlanivimab Monoclonal Antibody
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Ninety-second panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value G: Sarilumab
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Ninety-third panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value G: REGN-COV2 Monoclonal Antibody
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Ninety-fourth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value G: Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Ninety-fifth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value H: Tocilizumab
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Ninety-sixth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value H: Other New Technology Monoclonal Antibody
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Ninety-seventh panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value H: Axicabtagene Ciloleucel Immunotherapy
    Second choice is value J: Tisagenlecleucel Immunotherapy
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Ninety-eighth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value K: Fosfomycin Anti-infective
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Ninety-ninth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value K: Idecabtagene Vicleucel Immunotherapy
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: One hundredth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value K: Sulbactam-Durlobactam
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: One hundred First panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value L: CD24Fc Immunomodulator
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: One hundred Second panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value L: Lifileucel Immunotherapy
    Second choice is value M: Brexucabtagene Autoleucel Immunotherapy
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: One hundred Third panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value N: Meropenem-vaborbactam Anti-infective
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: One hundred Fourth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value N: Lisocabtagene Maraleucel Immunotherapy
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: One hundred Fifth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value P: Glofitamab Antineoplastic
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: One hundred Sixth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value Q: Tagraxofusp-erzs Antineoplastic
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: One hundred Seventh panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value Q: Posoleucel
    Second choice is value R: Rezafungin
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: One hundred Eighth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 3 choices.
    First choice is value S: Iobenguane I-131 Antineoplastic
    Second choice is value U: Imipenem-cilastatin-relebactam Anti-infective
    Third choice is value W: Caplacizumab
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: One hundred Ninth panel of table X W 0
  Fourth character (Body Part) is value 5: Peripheral Artery
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value T: Melphalan Hydrochloride Antineoplastic
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: One hundred Tenth panel of table X W 0
  Fourth character (Body Part) is value 9: Nose
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Device / Substance / Technology) is value M: Esketamine Hydrochloride
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: One hundred Eleventh panel of table X W 0
  Fourth character (Body Part) is value D: Mouth and Pharynx
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value 3: Maribavir Anti-infective
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: One hundred Twelfth panel of table X W 0
  Fourth character (Body Part) is value D: Mouth and Pharynx
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value 6: Lefamulin Anti-infective
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: One hundred Thirteenth panel of table X W 0
  Fourth character (Body Part) is value D: Mouth and Pharynx
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value 8: Uridine Triacetate
  Seventh character (Qualifier) is value 2: New Technology Group 2

No change: One hundred Fourteenth panel of table X W 0
  Fourth character (Body Part) is value D: Mouth and Pharynx
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value F: Other New Technology Therapeutic Substance
    Second choice is value J: Apalutamide Antineoplastic
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: One hundred Fifteenth panel of table X W 0
  Fourth character (Body Part) is value D: Mouth and Pharynx
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value J: Quizartinib Antineoplastic
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: One hundred Sixteenth panel of table X W 0
  Fourth character (Body Part) is value D: Mouth and Pharynx
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value K: Sabizabulin
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: One hundred Seventeenth panel of table X W 0
  Fourth character (Body Part) is value D: Mouth and Pharynx
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value L: Erdafitinib Antineoplastic
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: One hundred Eighteenth panel of table X W 0
  Fourth character (Body Part) is value D: Mouth and Pharynx
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value M: Baricitinib
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: One hundred Nineteenth panel of table X W 0
  Fourth character (Body Part) is value D: Mouth and Pharynx
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value N: SER-109
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: One hundred Twentieth panel of table X W 0
  Fourth character (Body Part) is value D: Mouth and Pharynx
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value R: Venetoclax Antineoplastic
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: One hundred Twenty-first panel of table X W 0
  Fourth character (Body Part) is value D: Mouth and Pharynx
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value R: Fostamatinib
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: One hundred Twenty-second panel of table X W 0
  Fourth character (Body Part) is value D: Mouth and Pharynx
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value T: Ruxolitinib
    Second choice is value V: Gilteritinib Antineoplastic
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: One hundred Twenty-third panel of table X W 0
  Fourth character (Body Part) is value G: Upper GI
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value 3: Maribavir Anti-infective
    Second choice is value K: Sabizabulin
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: One hundred Twenty-fourth panel of table X W 0
  Fourth character (Body Part) is value G: Upper GI
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Device / Substance / Technology) is value M: Baricitinib
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: One hundred Twenty-fifth panel of table X W 0
  Fourth character (Body Part) is value G: Upper GI
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Device / Substance / Technology) is value R: Fostamatinib
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: One hundred Twenty-sixth panel of table X W 0
  Fourth character (Body Part) is value G: Upper GI
  Fifth character (Approach) is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Device / Substance / Technology) is value 8: Mineral-based Topical Hemostatic Agent
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: One hundred Twenty-seventh panel of table X W 0
  Fourth character (Body Part) is value H: Lower GI
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value 3: Maribavir Anti-infective
    Second choice is value K: Sabizabulin
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: One hundred Twenty-eighth panel of table X W 0
  Fourth character (Body Part) is value H: Lower GI
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Device / Substance / Technology) is value M: Baricitinib
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: One hundred Twenty-ninth panel of table X W 0
  Fourth character (Body Part) is value H: Lower GI
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Device / Substance / Technology) is value R: Fostamatinib
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: One hundred Thirtieth panel of table X W 0
  Fourth character (Body Part) is value H: Lower GI
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Device / Substance / Technology) is value X: Broad Consortium Microbiota-based Live Biotherapeutic Suspension
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: One hundred Thirty-first panel of table X W 0
  Fourth character (Body Part) is value H: Lower GI
  Fifth character (Approach) is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Device / Substance / Technology) is value 8: Mineral-based Topical Hemostatic Agent
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: One hundred Thirty-second panel of table X W 0
  Fourth character (Body Part) is value Q: Cranial Cavity and Brain
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 1: Eladocagene exuparvovec
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: One hundred Thirty-third panel of table X W 0
  Fourth character (Body Part) is value V: Bones
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value P: Antibiotic-eluting Bone Void Filler
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: table X X 2
  First character (Section) is value X: New Technology
  Second character (Body System) is value X: Physiological Systems
  Third character (Operation) is value 2: Monitoring: Determining the level of a physiological or physical function repetitively over a period of time

No change: First panel of table X X 2
  Fourth character (Body Part) is value 0: Central Nervous
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value 8: Brain Electrical Activity, Computer-aided Detection and Notification
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: Second panel of table X X 2
  Fourth character (Body Part) is value F: Musculoskeletal
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value W: Muscle Compartment Pressure, Micro-Electro-Mechanical System
  Seventh character (Qualifier) is value 9: New Technology Group 9

FY2024: Third panel of table X X 2
  Fourth character (Body Part) is value K: Subcutaneous Tissue
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value P: Interstitial Fluid Volume, Sub-Epidermal Moisture using Electrical Biocapacitance
  Seventh character (Qualifier) is value 9: New Technology Group 9
